Platelet-activating factor antagonists decrease follicular dendritic-cell stimulation of human B lymphocytes.

Area of Science:

• Immunology
• Cell Biology
• Biochemistry

Background:

• B lymphocytes and B-lymphoblastoid cell lines express platelet-activating factor (PAF) receptors.
• Follicular dendritic cells (FDCs) in germinal centers present immune complexes to B lymphocytes, potentially releasing lipid mediators like PAF.
• The role of PAF in the interaction between FDCs and B lymphocytes requires investigation.

Purpose of the Study:

• To investigate the effect of the PAF antagonist WEB 2170 on tonsillar B lymphocyte activation mediated by FDCs.
• To determine if PAF receptor blockade influences B lymphocyte proliferation and immunoglobulin secretion in the context of FDC interaction.

Main Methods:

• Isolation of FDCs from tonsils using Bovine Serum Albumin (BSA) gradient centrifugation.
• Co-culture of FDCs with isolated B cells in the presence or absence of the PAF antagonist WEB 2170.
• Assessment of B-lymphocyte proliferation via [3H]-thymidine incorporation and immunoglobulin (IgG, IgM) secretion using ELISA.

Main Results:

• WEB 2170 significantly inhibited B-lymphocyte proliferation ([3H]-thymidine incorporation) by up to 35%.
• Secretion of IgG and IgM was reduced by up to 50% upon treatment with WEB 2170.
• No toxicity was observed, and WEB 2170 did not affect spontaneous Ig production in the absence of FDCs, indicating a specific effect on FDC-mediated activation.

Conclusions:

• Endogenous platelet-activating factor (PAF) production appears to be crucial for the interaction between B lymphocytes and FDCs.
• The PAF receptor antagonist WEB 2170 effectively inhibits FDC-driven B lymphocyte activation, proliferation, and immunoglobulin secretion.
• These findings highlight the importance of the PAF signaling pathway in germinal center B cell responses.